Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why

Shares of the commercial-stage biotechnology company, Krystal Biotech, Inc. (KRYS) , surged 36.5% year to date against the industry's decline of 4.3%. This was due to the strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress. Another candidate, KB408, is being evaluated for the treatment of alpha-1 antitrypsin deficiency (AATD). Krystal dosed the first patient in phase I SERPENTINE-1 study in adult patients with AATD. Recruitment is ongoing and the company remains on track to re ...